Publications
A brief listing of relevant scientific publications and presentations by UNC Lineberger Clinical Immunotherapy Program faculty:
Immunogenicity of CAR T cells in cancer therapy. Wagner DL, Fritsche E, Pulsipher MA, Ahmed N, Hamieh M, Hegde M, Ruella M, Savoldo B, Shah NN, Turtle CJ, Wayne AS, Abou-El-Enein M.Wagner DL, et al. Nat Rev Clin Oncol. 2021 Feb 25. doi: 10.1038/s41571-021-00476-2. Online ahead of print.
Utility of Safety Switch to Abrogate CD19.CAR T Cell-Associated Neurotoxicity. Foster MC, Savoldo B, Lau W, Rubinos CA, Grover N, Armistead PM, Coghill JM, Hagan RS, Morrison JK, Cheng C, Laing S, Ivanova A, West J, Foster A, Serody J, Dotti G. Blood. 2021 Feb 23:blood.2021010784. doi: 10.1182/blood.2021010784. Online ahead of print.
Infusion of CD30 CAR T Cells Is Safe and Effective As Consolidation Following Autologous Hematopoietic Stem Cell Transplant. Riches ML, Shea TC, Ivanova A, Cheng C, Laing S, Seegars MB, Dotti G, Savoldo B, Grover NS, Serody JS. Transplant and Cellular Therapy Meetings 2021.
Modifications to the Framework Regions Eliminate Chimeric Antigen Receptor Tonic Signaling. Landoni E, Fucá G, Wang J, Chirasani VR, Yao Z, Dukhovlinova E, Ferrone S, Savoldo B, Hong LK, Shou P, Musio S, Padelli F, Finocchiaro G, Droste M, Kuhlman B, Shamshiev A, Pellegatta S, Dokholyan NV, Dotti G. Cancer Immunol Res. 2021 Feb 5:canimm.0451.2020. doi: 10.1158/2326-6066.CIR-20-0451. Online ahead of print.
Preclinical Evaluation of B7-H3-Specific Chimeric Antigen Receptor T cells for the Treatment of Acute Myeloid Leukemia. Lichtman EI, Du H, Shou P, Song F, Suzuki K, Ahn S, Li G, Ferrone S, Su L, Savoldo B, Dotti G. Clin Cancer Res. 2021 Feb 2:clincanres.2540.2020. doi: 10.1158/1078-0432.CCR-20-2540. Epub ahead of print.
STING agonist promotes CAR T cell trafficking and persistence in breast cancer. Xu N, Palmer DC, Robeson AC, Shou P, Bommiasamy H, Laurie SJ, Willis C, Dotti G, Vincent BG, Restifo NP, Serody JS. J Exp Med. 2021 Feb 1;218(2):e20200844. doi: 10.1084/jem.20200844.
Extending the Promise of Chimeric Antigen Receptor T-Cell Therapy Beyond Targeting CD19 + Tumors. Grover NS, Tschernia N, Dotti G, Savoldo B. J Clin Oncol. 2021 Feb 10;39(5):499-513. doi: 10.1200/JCO.20.01738. Epub 2021 Jan 12.
Pursuing Better Biomarkers for Immunotherapy Response in Cancer Through a Crowdsourced Data Challenge. Benjamin G. Vincent, Joseph D. Szustakowski, Parul Doshi, Michael Mason, Justin Guinney, and David P. Carbone. JCO Precision Oncology 2021;5:51-54. doi: 10.1200/PO.20.00371 Published online 2021 Jan 8.
Long-term remission in multiply relapsed enteropathy-associated T-cell lymphoma following CD30 CAR T-cell therapy. Voorhees TJ, Ghosh N, Grover N, Block J, Cheng C, Morrison K, Ivanova A, Dotti G, Serody J, Savoldo B, Beaven AW. Blood Adv. 2020 Dec 8;4(23):5925-5928. doi: 10.1182/bloodadvances.2020003218.
Improved T-cell Receptor Diversity Estimates Associate with Survival and Response to Anti-PD-1 Therapy. Bortone DS, Woodcock MG, Parker JS, Vincent BG. Cancer Immunol Res. 2021 Jan;9(1):103-112. doi: 10.1158/2326-6066.CIR-20-0398. Epub 2020 Nov 11.
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, Wang T, Shea TC, Rooney CM, Dittus C, Park SI, Gee AP, Eldridge PW, McKay KL, Mehta B, Cheng CJ, Buchanan FB, Grilley BJ, Morrison K, Brenner MK, Serody JS, Dotti G, Heslop HE, Savoldo B. J Clin Oncol. 2020 Nov 10;38(32):3794-3804. doi: 10.1200/JCO.20.01342. Epub 2020 Jul 23.
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis. Heczey A, Courtney AN, Montalbano A, Robinson S, Liu K, Li M, Ghatwai N, Dakhova O, Liu B, Raveh-Sadka T, Chauvin-Fleurence CN, Xu X, Ngai H, Di Pierro EJ, Savoldo B, Dotti G, Metelitsa LS Nat Med. 2020 Oct 12. doi: 10.1038/s41591-020-1074-2. Online ahead of print.
GD2-specific CAR T cells encapsulated in an injectable hydrogel control retinoblastoma and preserve vision. Wang K, Chen Y, Ahn S, Zheng M, Landoni E, Dotti G, Savoldo B, Han Z. Nat Cancer 1, 990–997 2020. doi: 10.1038/s43018-020-00119-y.
Enhancing Chimeric Antigen Receptor T cell Efficacy in Solid Tumors. Fucá G, Reppel L, Landoni E, Savoldo B, Dotti G. Clin Cancer Res. 2020 June 1; (26)(11) 2444-2451; doi: 10.1158/1078-0432.CCR-19-1835.
Interleukin-23 engineering improves CAR T cell function in solid tumors. Ma X, Shou P, Smith C, Chen Y, Du H, Sun C, Porterfield Kren N, Michaud D, Ahn S, Vincent B, Savoldo B, Pylayeva-Gupta Y, Zhang S, Dotti G, Xu Y. Nat Biotechnol. 2020 Feb 3; doi: 10.1038/s41587-019-0398-2.
THEMIS-SHP1 Recruitment by 4-1BB Tunes LCK-Mediated Priming of Chimeric Antigen Receptor-Redirected T Cells. Sun C, Shou P, Du H, Hirabayashi K, Chen Y, Herring LE, Ahn S, Xu Y, Suzuki K, Li G, Tsahouridis O, Su L, Savoldo B, Dotti G. Cancer Cell. 2020 Feb 10;37(2):216-225.e6. doi: 10.1016/j.ccell.2019.12.014. Epub 2020 Jan 30.
A High-Avidity T-cell Receptor Redirects Natural Killer T-cell Specificity and Outcompetes the Endogenous Invariant T-cell Receptor. Landoni E, Smith CC, Fucá G, Chen Y, Sun C, Vincent BG, Metelitsa LS, Dotti G, Savoldo B. Cancer Immunol Res. 2020 Jan;8(1):57-69. doi: 10.1158/2326-6066.CIR-19-0134. Epub 2019 Nov 12.
B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres. Nehama D, Di Ianni N, Musio S, Du H, Patané M, Pollo B, Finocchiaro G, Park JJH, Dunn DE, Edwards DS, Damrauer JS, Hudson H, Floyd SR, Ferrone S, Savoldo B, Pellegatta S, Dotti G. EBioMedicine. 2019 Sep;47:33-43. doi: 10.1016/j.ebiom.2019.08.030. Epub 2019 Aug 26.
Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma. Sun C, Mahendravada A, Ballard B, Kale B, Ramos C, West J, Maguire T, McKay K, Lichtman E, Tuchman S, Dotti G, Savoldo B. Oncotarget. 2019 Mar 22;10(24):2369-2383. doi: 10.18632/oncotarget.26792. eCollection 2019 Mar 22.
Cancer Immunotherapy with T Cells Carrying Bispecific Receptors That Mimic Antibodies. Ahn S, Li J, Sun C, Gao K, Hirabayashi K, Li H, Savoldo B, Liu R, Dotti G. Cancer Immunol Res. 2019 May;7(5):773-783. doi: 10.1158/2326-6066.CIR-18-0636. Epub 2019 Mar 6.
Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells. Du H, Hirabayashi K, Ahn S, Kren NP, Montgomery SA, Wang X, Tiruthani K, Mirlekar B, Michaud D, Greene K, Herrera SG, Xu Y, Sun C, Chen Y, Ma X, Ferrone CR, Pylayeva-Gupta Y, Yeh JJ, Liu R, Savoldo B, Ferrone S, Dotti G. Cancer Cell. 2019 Feb 11;35(2):221-237.e8. doi: 10.1016/j.ccell.2019.01.002.
Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15. Chen Y, Sun C, Landoni E, Metelitsa L, Dotti G, Savoldo B. Clin Cancer Res. 2019 May 1;25(9):2915-2924. doi: 10.1158/1078-0432.CCR-18-1811. Epub 2019 Jan 7.
In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin’s Lymphomas. Ramos CA, Rouce R, Robertson CS, Reyna A, Narala N, Vyas G, Mehta B, Zhang H, Dakhova O, Carrum G, Kamble RT, Gee AP, Mei Z, Wu MF, Liu H, Grilley B, Rooney CM, Heslop HE, Brenner MK, Savoldo B, Dotti G. Mol Ther. 2018 Dec 5;26(12):2727-2737. doi: 10.1016/j.ymthe.2018.09.009. Epub 2018 Sep 13.
CD30-Redirected Chimeric Antigen Receptor T Cells Target CD30+ and CD30– Embryonal Carcinoma via Antigen-Dependent and Fas/FasL Interactions. Hong LK, Chen Y, Smith CC, Montgomery SA, Vincent BG, Dotti G, Savoldo B. Cancer Immunol Res. 2018 Oct;6(10):1274-1287. doi: 10.1158/2326-6066.CIR-18-0065. Epub 2018 Aug 7.
Constitutive and TNFα-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy. Pellegatta S, Savoldo B, Di Ianni N, Corbetta C, Chen Y, Patané M, Sun C, Pollo B, Ferrone S, DiMeco F, Finocchiaro G, Dotti G. Sci Transl Med. 2018 Feb 28;10(430). doi: 10.1126/scitranslmed.aao2731.
Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells. Iulia Diaconu, Brandon Ballard, Ming Zhang, Yuhui Chen, John West, Gianpietro Dotti, Barbara Savoldo Mol Ther. 2017 Mar 1;25(3):580-592. doi: 10.1016/j.ymthe.2017.01.011. Epub 2017 Feb 8.
Clonal Dynamics In Vivo of Virus Integration Sites of T Cells Expressing a Safety Switch. Chang EC, Liu H, West JA, Zhou X, Dakhova O, Wheeler DA, Heslop HE, Brenner MK, Dotti G. Mol Ther. 2016 Apr;24(4):736-45. doi: 10.1038/mt.2015.217. Epub 2015 Dec 7.
Inducible apoptosis as a safety switch for adoptive cell therapy. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, Straathof K, Liu E, Durett AG, Grilley B, Liu H, Cruz CR, Savoldo B, Gee AP, Schindler J, Krance RA, Heslop HE, Spencer DM, Rooney CM, Brenner MK. N Engl J Med. 2011 Nov 3;365(18):1673-83. doi: 10.1056/NEJMoa1106152.